Clinical trials: Kidney Disease
Chronic Kidney Disease and Hypertension
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in…
- Trial name
- BaxDuo-Pacific (NCT06742723)
- Testing
- Baxdrostat/dapagliflozin
- Where
- 771 sites in United States, Argentina and 40 more
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
End Stage Kidney Disease (ESKD)
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in…
- Trial name
- NCT07619820
- Testing
- CSL300
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSL Behring
Diabetes Mellitus, Type 2
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.
- Trial name
- NCT01792518
- Testing
- Linagliptin 5mg
- Where
- 74 sites in United States, Canada and 10 more
- Volunteers
- 360 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Renal Cell
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive…
- Trial name
- NCT00130897
- Testing
- Sutent
- Where
- 271 sites in United States, Argentina and 48 more
- Sponsor
- Pfizer
Hypertension, Metabolic Syndrome
Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension
The objective of the study is to evaluate the safety of renal denervation using the iRF System and to understand any potential improvement in hypertension.
- Trial name
- RADAR (NCT04740723)
- Testing
- iRF System Renal Denervation
- Where
- 2 sites in Georgia
- Volunteers
- 30 people
- Sponsor
- Metavention
IgA Nephropathy (IgAN)
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Efficacy and safety of MY008211A in IgAN patients
- Trial name
- NCT06687174
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Renal Impairment
A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment
This is a Phase 1, open label, single-dose, pharmacokinetic study to be conducted in male and female subjects with normal and impaired renal function.
- Trial name
- NCT02709382
- Testing
- Cefepime and Tazobactam combination
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Wockhardt
Heart Failure
Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment Clinical Trial
This is a feasibility study enrolling up to 40 patients in Australia and Europe. The primary aim of the study is to demonstrate the renal denervation with the Symplicity Catheter is safe and determine the evidence of a response…
- Trial name
- SymplicityHF (NCT01392196)
- Testing
- Renal Denervation
- Where
- Australia
- Volunteers
- 39 people
- Sponsor
- Medtronic Vascular
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma.
- Trial name
- NCT00726323
- Testing
- foretinib (formerly GSK1363089 or XL880)
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease (ESRD)
Automated Setting of Individualized Sodium Technology
The ASIST study is a medical device study testing the safety and efficacy of a new hemodialysis machine software in chronic haemodialysis patients.
- Trial name
- ASIST (NCT02795286)
- Testing
- Artis Haemodialysis Machine w/ ASIST Software - Isonatremic, Artis Haemodialysis Machine w/ ASIST Software - Isotonic, Artis Haemodialysis Machine w/o ASIST Software
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vantive Health LLC
Chronic Kidney Disease
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease.
- Trial name
- NCT03594110
- Testing
- Empagliflozin
- Where
- 240 sites in United States, Canada and 6 more
- Volunteers
- 6,609 people
- Sponsor
- Boehringer Ingelheim
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Chronic Kidney Disease
Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
The purpose of this study is to determine the durability of seroprotection of HEPLISAV™ and Engerix-B® and the number of injections of each vaccine needed to maintain seroprotection in a cohort of chronic kidney disease (CKD)…
- Trial name
- NCT01282762
- Testing
- HEPLISAV, Engerix-B
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Dynavax Technologies Corporation
Carcinoma, Renal Cell
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
- Trial name
- NCT00077974
- Testing
- SU011248
- Where
- 15 sites in United States
- Volunteers
- 106 people
- Sponsor
- Pfizer
Chronic Kidney Disease
Forxiga CKD Japan Post-Marketing Surveillance (PMS)
To capture safety when Forxige is administrated to CKD patients in the real world setting
- Trial name
- NCT05306210
- Where
- 46 sites in Japan
- Volunteers
- 1,029 people
- Sponsor
- AstraZeneca
Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency
Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency
The main function of Guilu Erxian Oral Liquid is to warm the shen (kindney) and replenish essence. It is used for chronic shen (kindney) deficiency, waist and knee weakness, spermatorrhea and impotence.
- Trial name
- NCT07270146
- Testing
- Guilu Erxian Oral Liquid, Wuzi Yanzong oral liquid
- Where
- China
- Volunteers
- 360 people
- Sponsor
- DongE E Jiao Coporation Limited
Acute Kidney Injury
Clinical Validation of NAVOY® Acute Kidney Injury in Swedish ICU Patients
The study aims to evaluate the performance of the prediction algorithm NAVOY® AKI in a Swedish adult ICU patient population versus fulfilment of KDIGO diagnostic criteria.
- Trial name
- ExTRACT (NCT05424874)
- Where
- Sweden
- Volunteers
- 304 people
- Sponsor
- AlgoDx
Chronic Kidney Failure
Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
- Trial name
- NCT00844662
- Testing
- Fermagate, Sevelamer hydrochloride
- Where
- 109 sites in United States, Belgium and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Ineos Healthcare Limited
Contrast Induced Acute Kidney Injury
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary…
- Trial name
- NCT05758896
- Testing
- Isuzinaxib (APX-115)
- Where
- 14 sites in United States, South Korea
- Volunteers
- 218 people
- Sponsor
- Aptabio Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.